MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of innovative small molecule and biologic therapies. The company’s research focuses primarily on oncology and immunology, with a pipeline that spans from early preclinical assets through Phase 1 clinical trials. MIRA’s approach combines state-of-the-art target identification and medicinal chemistry to address high-unmet needs in solid tumors and autoimmune disorders.
At the core of MIRA’s operations is its integrated drug discovery platform, which leverages structural biology, high-throughput screening and translational biomarkers. This platform enables the rapid optimization of lead compounds and the generation of novel clinical candidates. In addition to internal research programs, MIRA collaborates with academic institutions and biopharmaceutical partners to extend its reach into emerging modalities, including antibody-drug conjugates and next-generation immune checkpoint modulators.
Founded in 2018 and headquartered in Cambridge, Massachusetts, MIRA Pharmaceuticals has built a global footprint with strategic partnerships across North America, Europe and Asia. The company’s international alliances support both preclinical research and clinical development, facilitating access to specialized manufacturing capabilities and patient populations. Over the past several years, MIRA has secured multiple licensing agreements to advance its lead programs into pivotal studies and expand its portfolio through in-licensing opportunities.
Under the leadership of Chief Executive Officer Dr. Alexandra King and Chief Scientific Officer Dr. Michael Evans, MIRA maintains a disciplined pipeline strategy aimed at delivering first-in-class or best-in-class therapeutics. The company’s management team brings extensive experience in drug development, regulatory affairs and commercialization, guiding MIRA through critical milestones as it works to bring new treatment options to patients worldwide.
